FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology.
作者信息
Russell Elizabeth S, Aubrun Elodie, Moga Daniela C, Guedes Sandra, Camelo Castillo Wendy, Hardy Janet R, Cole J Alexander, Jagun Oladayo
机构信息
Merck & Co., Inc., Rahway, NJ, USA.
Novartis Pharma AG, Basel, Switzerland.
出版信息
J Clin Transl Sci. 2023 May 2;7(1):e101. doi: 10.1017/cts.2023.515. eCollection 2023.
Abstract
摘要
相似文献
1
FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology.美国食品药品监督管理局（FDA）关于改善临床试验多样性的草案指南：药物流行病学的机遇
J Clin Transl Sci. 2023 May 2;7(1):e101. doi: 10.1017/cts.2023.515. eCollection 2023.
2
Clinical epidemiology and pharmacoepidemiology studies with real-world databases.临床流行病学和基于真实世界数据库的药物流行病学研究。
Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(10):517-528. doi: 10.2183/pjab.98.026.
3
FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.美国食品药品监督管理局关于适应性设计临床试验的草案指南：辉瑞公司的观点。
J Biopharm Stat. 2010 Nov;20(6):1143-9. doi: 10.1080/10543406.2010.514456.
4
What is pharmacoepidemiology? Definition, methods, interest and clinical applications.什么是药物流行病学？定义、方法、意义及临床应用。
Therapie. 2019 Apr;74(2):169-174. doi: 10.1016/j.therap.2018.08.001. Epub 2018 Oct 10.
5
New FDA draft guidance on immunogenicity.美国食品药品监督管理局关于免疫原性的新草案指南。
AAPS J. 2014 May;16(3):499-503. doi: 10.1208/s12248-014-9587-6. Epub 2014 Mar 29.
6
A Framework for Extension Studies Using Real-World Data to Examine Long-Term Safety and Effectiveness.利用真实世界数据开展扩展研究的框架，以评估长期安全性和有效性。
Ther Innov Regul Sci. 2022 Jan;56(1):15-22. doi: 10.1007/s43441-021-00322-8. Epub 2021 Jul 12.
7
Regulatory Forum Opinion Piece: Review of FDA Draft Guidance Testicular Toxicity-Evaluation during Drug Development Guidance for Industry.监管论坛观点文章：美国食品药品监督管理局（FDA）《药物研发期间睾丸毒性评估行业指南》草案综述
Toxicol Pathol. 2016 Oct;44(7):927-30. doi: 10.1177/0192623316656416. Epub 2016 Jun 29.
8
A review of the FDA draft guidance document for software validation: guidance for industry.美国食品药品监督管理局（FDA）软件验证指南文件草案：行业指南综述。
Qual Assur. 1999;7(1):49-55. doi: 10.1080/105294100277723.
9
Pharmacoepidemiology and Big Data Analytics: Challenges and Opportunities when Moving towards Precision Medicine.药物流行病学与大数据分析：迈向精准医学过程中的挑战与机遇
Chimia (Aarau). 2019 Dec 18;73(12):1012-1017. doi: 10.2533/chimia.2019.1012.
引用本文的文献
1
Clinical Research Informatics: a Decade-in-Review.临床研究信息学：十年回顾
Yearb Med Inform. 2024 Aug;33(1):127-142. doi: 10.1055/s-0044-1800732. Epub 2025 Apr 8.
2
Promoting Diversity through an Understanding of Barriers and Drivers for Inclusive Clinical Trials.通过理解包容性临床试验的障碍和驱动因素促进多样性
Ther Innov Regul Sci. 2025 May;59(3):596-605. doi: 10.1007/s43441-025-00751-9. Epub 2025 Feb 26.
3
Linking clinical trial participants to their U.S. real-world data through tokenization: A practical guide.通过令牌化将临床试验参与者与其美国真实世界数据相链接：实用指南。
Contemp Clin Trials Commun. 2024 Aug 17;41:101354. doi: 10.1016/j.conctc.2024.101354. eCollection 2024 Oct.
4
RIAIT (Italian Registry of Allergen Immunotherapy): Protocol for a New Tool in a New Vision of Disease-Modifying Therapy for Allergists.意大利变应原免疫治疗登记处（RIAIT）：为过敏症专科医生提供疾病修饰治疗新视野下的新工具方案。
J Pers Med. 2024 Aug 12;14(8):854. doi: 10.3390/jpm14080854.
5
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.东南地区一家 NCI 指定综合性癌症中心 I 期临床试验人群的社会人口统计学特征变化。
Oncologist. 2023 Dec 11;28(12):1055-1063. doi: 10.1093/oncolo/oyad181.
本文引用的文献
1
Issues With Variability in Electronic Health Record Data About Race and Ethnicity: Descriptive Analysis of the National COVID Cohort Collaborative Data Enclave.电子健康记录中种族和民族数据的变异性问题：国家新冠队列协作数据中心的描述性分析
JMIR Med Inform. 2022 Sep 6;10(9):e39235. doi: 10.2196/39235.
2
Real-world data: Assessing electronic health records and medical claims data to support regulatory decision-making for drug and biological products.真实世界数据：评估电子健康记录和医疗理赔数据以支持药品和生物制品的监管决策。
Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):717-720. doi: 10.1002/pds.5444. Epub 2022 May 3.
3
Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?种族间药代动力学的差异——有更多的共同点还是更多的分歧？
Pharmacol Res Perspect. 2021 Dec;9(6):e00890. doi: 10.1002/prp2.890.
4
Population diversity in oncology drug responses and implications to drug development.肿瘤学药物反应中的人群多样性及其对药物开发的影响。
Chin Clin Oncol. 2019 Jun;8(3):24. doi: 10.21037/cco.2019.05.01.
Zotero 插件